A Study of Tumor Imaging With Multispectral Optoacoustic Tomography

Active, not recruitingOBSERVATIONAL
Enrollment

12

Participants

Timeline

Start Date

July 27, 2022

Primary Completion Date

July 27, 2026

Study Completion Date

July 27, 2026

Conditions
Breast CancerMelanoma
Interventions
DIAGNOSTIC_TEST

Multispectral Optoacoustic Tomography Imaging

Each participants will undergo MSOT imaging of the suspicious breast tumor detected with ultrasound imaging and any additional lesion present in either breast before undergoing ultrasound-guided breast biopsy as the standard of care. Melanoma participants with pathologically confirmed ITM will undergo MSOT imaging following physical exam and biopsy. Melanoma patients receiving immunotherapy will undergo MSOT imaging prior to and following immunotherapy.

Trial Locations (4)

10021

Memorial Sloan - Kettering Cancer Center, New York

11725

Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (Consent only), Commack

07645

Memorial Sloan Kettering Bergen (Consent only ), Montvale

Unknown

Helmholtz Institute (Data Analysis Only), Munich

All Listed Sponsors
lead

Memorial Sloan Kettering Cancer Center

OTHER